Article Link: FDA Approves Jeuveau (prabotulinumtoxinA-xvfs) for Temporary Improvement in the Appearance of Frown Lines NEWPORT BEACH, Ca...
FDA Approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of Advair Diskus
Article Link: FDA Approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of Advair Diskus HE...
FDA Approves Osphena (ospemifene) for Moderate to Severe Vaginal Dryness Due to Menopause
Article Link: FDA Approves Osphena (ospemifene) for Moderate to Severe Vaginal Dryness Due to Menopause BLAINVILLE, QC, January 29, 2019 ...
FDA Approves Imbruvica (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Article Link: FDA Approves Imbruvica (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chr...
FDA Approves Tosymra (sumatriptan) Nasal Spray for Acute Treatment of Migraine
Article Link: FDA Approves Tosymra (sumatriptan) Nasal Spray for Acute Treatment of Migraine January 27, 2019 — Dr. Reddy’s Laborat...
FDA Approves Use of 0.5 mL Dose of Fluzone Quadrivalent (influenza vaccine) in Children as Young as 6 Months of Age
Article Link: FDA Approves Use of 0.5 mL Dose of Fluzone Quadrivalent (influenza vaccine) in Children as Young as 6 Months of Age BRIDGEW...
FDA Approves Ontruzant (trastuzumab-dttb), a Biosimilar to Herceptin
Article Link: FDA Approves Ontruzant (trastuzumab-dttb), a Biosimilar to Herceptin January 18, 2019 — FDA today approved Ontruzant ...
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
Article Link: Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma AL...
FDA Approves Expanded Use of Adacel (Tdap) Vaccine for Repeat Vaccination
Article Link: FDA Approves Expanded Use of Adacel (Tdap) Vaccine for Repeat Vaccination BRIDGEWATER, N.J., Jan. 14, 2019 /PRNewswire/ ...
KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of Apadaz (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)
Article Link: KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of Apadaz (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydr...
